The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: An analysis of the randomised ABCSG-6a trial

British Journal of Cancer

Volumn 109, Issue 3, 2013, Pages 589-596

  Gnant, M ^a   Pfeiler, G ^a   Stoger H ^b   Mlineritsch, B ^c   Fitzal, F ^a   Balic, M ^b   Kwasny, W ^d   Seifert, M ^a   Stierer, M ^e   Dubsky, P ^a   Greil, R ^c   Steger, G ^a   Samonigg, H ^b   Fesl, C ^f   Jakesz, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Rheumatology and Infectious Diseases   (Austria)

^d Hospital Wiener Neustadt   (Austria)

^e HANUSCH HOSPITAL   (Austria)

^f Austrian Breast and Colorectal Cancer Study Group   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; TAMOXIFEN;

ADULT; AGED; AMENORRHEA; ARTICLE; ASTHENIA; BLEEDING; BODY MASS; BODY WEIGHT; BONE PAIN; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ECZEMA; FEMALE; FEVER; HAIR LOSS; HEADACHE; HEART ARRHYTHMIA; HEMATURIA; HOT FLUSH; HUMAN; INFECTION; MAJOR CLINICAL STUDY; NAUSEA; OBESITY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PERICARDITIS; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SKIN TOXICITY; SOMNOLENCE; VAGINA DISCHARGE; VAGINAL DRYNESS; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; OBESITY; OVERWEIGHT; POSTMENOPAUSE; RETROSPECTIVE STUDIES; TRIAZOLES; YOUNG ADULT;

EID: 84883202487     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.367     Document Type: Article

References (20)

1. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28: 3784-3796.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemo-therapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
3. Ewertz M, Jensen MB, Gunnarsdóttir KÁ, Højris I, Jakobsen EH, Nielsen D, Stenbygaard LE, Tange UB, Cold S (2011) Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29: 25-31.
4. Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303: 235-241.
5. Fontein DB, Nortier JW, Liefers GJ, Putter H, Meershoek-Klein Kranenbarg E, van den Bosch J, Maartense E, Rutgers EJ, van de Velde CJ (2012) High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial. Eur J Surg Oncol 38: 110-117.
6. Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M (2012) Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 30: 2977-2980.
7. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK, Hood N (2012) Insulin-and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 30: 164-171.
8. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmeno-pausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793-1802.
9. Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M (2008) Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer 8: 411-417.
10. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99: 1845-1853.
11. Kwan ML, Chen WY, Kroenke CH, Weltzien EK, Beasley JM, Nechuta SJ, Poole EM, Lu W, Holmes MD, Quesenberry Jr CP, Pierce JP, Shu XO, Caan BJ (2012) Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 132: 729-739.
12. Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer Jr CE, Costantino JP, Wolmark N (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 26: 1965-1971.
13. Netherlands Trial Register Investigation on the Duration of Extended Adjuvant Letrozole Treatment http://www.trialregister.nl/trialreg/admin/rctview. asp?TC=3077.
14. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol (2007) 18(suppl 8): S26-S35.
15. Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 Trial. J Clin Oncol 29: 2653-2659.
16. Pfeiler G, Stoeger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil R, Fesl C, Gnant M (2013) Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone-receptor positive breast cancer-an analysis of 1509 patients of the ABCSG-06 trial. Br J Cancer 108: 1408-1414.
17. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14: 2738-2746.
18. Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W (2003) Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol 21: 984-990.
19. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28: 3411-3415.
20. Wolters R, Schwentner L, Regierer A,Wischnewsky M, Kreienberg R, Wöckel A (2012) Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Res Treat 131: 925-931.